R
Ruben A. Mesa
Researcher at University of Texas Health Science Center at San Antonio
Publications - 720
Citations - 35662
Ruben A. Mesa is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Myelofibrosis & Ruxolitinib. The author has an hindex of 78, co-authored 632 publications receiving 30126 citations. Previous affiliations of Ruben A. Mesa include Wrocław Medical University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Transplantation for myelofibrosis: Time for a randomized trial
TL;DR: Outcomes of a reduced intensity allogeneic transplant with the se of a fludarabine and alemtuzumab based conditioning regimen are reported in his edition of Leukemia Research and his latter paper raises several issues which remain concerning ransplant in MF patients.
Journal Article
Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic - an investigator lead randomized trial
Christine J. Harrison,Adam J. Mead,Anesh Panchal,Sonia Fox,Christina Yap,Aimee E Houlton,S Aliman,Marion Wood,Frederick Chen,Jason Coppell,Nicki Panoskaltsis,R. Scherber,H. Geyer,Amylou C. Dueck,Ruben A. Mesa,Mary Frances McMullin +15 more
Journal ArticleDOI
Optimizing Dose Titration Of Ruxolitinib: The COMFORT-I Experience
TL;DR: In COMFORT-I, most patients experienced a RUX dose adjustment in the first 12 weeks of treatment and stable doses were achieved with long-term therapy and dose titration allowed most patients to maintain adequate platelet counts.
Journal ArticleDOI
Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders Research Consortium (MPD-RC)
Vikas Gupta,Heidi E. Kosiorek,Rebecca B. Klisovic,John P. Galvin,Dmitriy Berenzon,Abdulraheem Yacoub,Ruben A. Mesa,Gianni Tognoni,Giuseppe Prosperini,Alessandra Di Lelio,Eliseo Serone,Lorenzo Marfisi,Alicia Orellano,Lee Potiphar,Mohamed E. Salama,Rona Singer Weinberg,Amylou C. Dueck,Adam J. Mead,John Mascarenhas,Ronald Hoffman +19 more
TL;DR: The hypothesis driving this trial was that pre-transplant JAK1/2 inhibition would result in an increase in performance status, reduction in splenomegaly and inflammatory cytokine expression leading to improved HCT outcome.
Journal ArticleDOI
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
Tariq I. Mughal,Naveen Pemmaraju,Bethan Psaila,Jerald P. Radich,Prithviraj Bose,Thomas Lion,Jean-Jacques Kiladjian,Raajit K. Rampal,Tania Jain,Srdnan Verstovsek,Abdulraheem Yacoub,Jorge E. Cortes,Ruben A. Mesa,Giuseppe Saglio,Richard A. Van Etten +14 more
TL;DR: It is discussed how alternative therapies could benefit patients with chronic myeloid leukemia who develop BCR‐ABL1 mutant subclones following ABL1‐tyrosine kinase inhibitor therapy and the merits of integrating activin receptor ligand traps, interferon‐α, and allografting in the current treatment algorithm for patients with myelofibrosis.